{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03410043","nct_id":"NCT03410043","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03410043. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Group I (LCT)","type":"EXPERIMENTAL"},{"description":"Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Group II (no LCT)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","National Comprehensive Cancer Network"],"completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"conditions":["Lung Non-Small Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage IIIB Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":{"count":173,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["AZD-9291","AZD9291","Mereletinib","Tagrisso"],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"},{"name":"Therapeutic Conventional Surgery","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-09-18","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy (LCT) for Patients With EGFR-Mutant Metastatic NSCLC (NORTHSTAR)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"From the start date of osimertinib assessed up to 4 years"}],"references":[],"start_date":{"date":"2018-01-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study","url":"https://clinicaltrials.gov/study/NCT03410043"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03410043"}